ID   Bliley
AC   CVCL_DN27
SY   TCC-Bliley
DR   GEO; GSM1974776
DR   Wikidata; Q54797355
RX   PubMed=22849686;
RX   PubMed=26842912;
RX   PubMed=27197945;
RX   PubMed=27257868;
RX   PubMed=29732388;
RX   PubMed=31175136;
CC   Part of: FACC canine tumor cell line panel.
CC   Doubling time: 20 hours (PubMed=27257868).
CC   Sequence variation: Mutation; VGNC; 38514; BRAF; Simple; p.Val588Glu (c.1763T>A); Zygosity=Heterozygous (PubMed=27197945; PubMed=31175136).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
CC   Breed/subspecies: Shetland Sheepdog.
ST   Source(s): PubMed=27197945; PubMed=31175136
ST   Dog FHC2010: 227,239
ST   Dog FHC2054: 151
ST   Dog FHC2079: 275
ST   Dog PEZ1: 115,127
ST   Dog PEZ3: 119,124
ST   Dog PEZ5: 103,115
ST   Dog PEZ6: 172,183
ST   Dog PEZ8: 240
ST   Dog PEZ12: 285
ST   Dog PEZ20: 176,180
DI   NCIt; C128126; Canine transitional cell carcinoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 29-06-23; Version: 9
//
RX   PubMed=22849686; DOI=10.2460/ajvr.73.8.1252;
RA   Urbasic A.S., Hynes S., Somrak A.J., Contakos S., Rahman M.M., Liu J.,
RA   MacNeill A.L.;
RT   "Oncolysis of canine tumor cells by myxoma virus lacking the serp2
RT   gene.";
RL   Am. J. Vet. Res. 73:1252-1261(2012).
//
RX   PubMed=26842912; DOI=10.1111/vco.12197;
RA   Hartley G., Faulhaber E.A., Caldwell A., Coy J., Kurihara J.N.,
RA   Guth A., Regan D.P., Dow S.W.;
RT   "Immune regulation of canine tumour and macrophage PD-L1 expression.";
RL   Vet. Comp. Oncol. 15:534-549(2017).
//
RX   PubMed=27197945; DOI=10.1111/vco.12192;
RA   Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.;
RT   "The Flint Animal Cancer Center (FACC) canine tumour cell line panel:
RT   a resource for veterinary drug discovery, comparative oncology and
RT   translational medicine.";
RL   Vet. Comp. Oncol. 15:481-492(2017).
//
RX   PubMed=27257868; DOI=10.1371/journal.pone.0156689;
RA   Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.;
RT   "Intrinsic radiosensitivity and cellular characterization of 27 canine
RT   cancer cell lines.";
RL   PLoS ONE 11:E0156689-E0156689(2016).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346;
RA   Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.;
RT   "Identifying candidate druggable targets in canine cancer cell lines
RT   using whole exome sequencing.";
RL   Mol. Cancer Ther. 18:1460-1471(2019).
//